The Achilles heel of glioblastoma
JLP Health and its partners discover combinatorial treatment option for incurable brain tumors
By studying the mechanism of actition from a widely used Nobel Prize winning antiti-malaria drug named Artemisinin, the authors were able to pharmacologically sensititize brain cancer cells to this natural substance and selectitively eliminate brain tumors in numerous relevant model systems.
JLP Health GmbH, a privately held biotechnology company developing innovative treatments for cancer and infectious diseases, rationally designed a novel and highly effective treatment strategy to selectively kill incurable brain tumors. The study was conducted in collaboration with researchers from the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) and the Medical University of Vienna (both Vienna, Austria) and is published in EMBO Molecular Medicine.
The discovery of the natural substance Artemisinin as an anti-malaria treatment from Traditional Chinese Medicines saved millions of lives and was awarded with the Nobel Prize in Physiology in 2015. Besides its anti-malaria activity, Artemisinin exerts cell toxicity and is therefore investigated
OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS. www.ots.at
© Copyright APA-OTS Originaltext-Service GmbH und der jeweilige Aussender